Pegtibatinase

The 'Homocystinuria - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights into 3+ companies and 3+ pipeline drugs for Homocystinuria, covering clinical and nonclinical stages, therapeutic assessments, and pipeline development activities.

Bronstein, Gewirtz & Grossman, LLC investigates Travere Therapeutics, Inc. (NASDAQ: TVTX) after the company paused enrollment in its Phase 3 HARMONY Study due to manufacturing issues. Travere's stock price fell 6.85% following the announcement.

Travere Therapeutics pauses subject enrolment in Phase III HARMONY Study of pegtibatinase for classical homocystinuria to implement manufacturing scale-up improvements, aiming to resume enrolment in 2026.

Travere Therapeutics pauses enrollment in Phase 3 HARMONY Study for pegtibatinase due to manufacturing scale-up issues, aiming to resume in 2026. Current patients continue receiving treatment unaffected by the pause.

Travere Therapeutics pauses enrollment in Phase 3 HARMONY Study for pegtibatinase due to unmet drug substance profile during scale-up. Current patients continue receiving study medication. Enrollment restart anticipated in 2026, delaying investments and reducing R&D expenses by over $30 million in 2025. Cash reserves expected to support operations through 2028.